메뉴 건너뛰기




Volumn 64, Issue 7, 2003, Pages 851-

Nonalcoholic steatohepatitis: A possible side effect of atypical antipsychotics [5]

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPENTIXOL; LIVER ENZYME; OLANZAPINE; RISPERIDONE;

EID: 0041805233     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0718f     Document Type: Letter
Times cited : (6)

References (4)
  • 1
    • 0034042934 scopus 로고    scopus 로고
    • Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
    • Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981
    • (2000) Am J Psychiatry , vol.157 , pp. 975-981
    • Henderson, D.C.1    Cagliero, E.2    Gray, C.3
  • 2
    • 0032724490 scopus 로고    scopus 로고
    • Olanzapine increases weight and serum triglyceride levels
    • Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770
    • (1999) J Clin Psychiatry , vol.60 , pp. 767-770
    • Osser, D.N.1    Najarian, D.M.2    Dufresne, R.L.3
  • 3
    • 0033038672 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
    • Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419
    • (1999) Gastroenterology , vol.116 , pp. 1413-1419
    • Matteoni, C.A.1    Younossi, Z.M.2    Gramlich, T.3
  • 4
    • 0032828612 scopus 로고    scopus 로고
    • Fatty liver and nonalcoholic steatohepatitis: Where do we stand and where are we going?
    • Lonardo A. Fatty liver and nonalcoholic steatohepatitis: where do we stand and where are we going? Dig Dis 1999;17:80-89
    • (1999) Dig Dis , vol.17 , pp. 80-89
    • Lonardo, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.